Feiyang Liu

Associate Professor
Research Interests
Combinatorial Drug Screening

Education background

2013/09-2016/11 Univerisity of Science and Technology of China, Biology department, Ph.D
2008/09-2011/06 China Pharmaceutical University, Integrated Traditional Chinese and Western Medicine, M.S.
2002/09-2008/06 Anhui Medical University, Pharmacy, B.S.

Research Experience

2017/01-now, Postdoctoral Associate, High Magnetic Field Laboratory, Chinese Academy of Sciences
2011/08-2013/08, Technician, High Magnetic Field Laboratory, Chinese Academy of Sciences

Publications

  1. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-289.
  2. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong#, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun*, Zhimin Zhai*, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7(29): 45562-45574.
  3. Feiyang Liu#, Jinhua Wang#, Xingxing Yang#, Binhua Li#, Hong Wu, Shuang Qi, Cheng Chen, Xiaochuan Liu, kailin Yu, Wenchao Wang, Zhao, Aoli Wang, Yongfei Chen, Li Wang, Nathanael S Gray, Jing Liu*, Xin Zhang*, Qingsong Liu*. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem. Biol. 2016, 11(6): 1537-1543.
  4. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen#, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, and Qingsong Liu*. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-3979.
  5. Hong Wu#, Wenchao Wang#, Feiyang Liu#, Ellen L. Weisberg, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang, Beilei Wang, Zheng Zhao, Douglas W. McMillin, Chen Hu, Hong Li, Jinhua Wang, Yanke Liang, Sara J. Buhrlage, Junting Liang, Jing Liu, Guang Yang, Jennifer R. Brown, Steven P. Treon, Constantine S. Mitsiades, James D. Griffin, Qingsong Liu*, Nathanael S. Gray*. Discovery of a Potent, Covalent BTK Inhibitor for B‑Cell Lymphoma, ACS Chem. Biol. 2014, 9(5): 1086-1091.
  6. Hyung-Gu Kim#, Li Tan#, Ellen L Weisberg#, Feiyang Liu#, Peter Canning#, Hwan Geun Choi#, Scott A Ezell, Hong Wu, Zheng Zhao, Jinhua Wang, Anna Mandinova, James D. Griffin, Alex N. Bullock, Qingsong Liu*, Sam W. Lee*, Nathanael S. Gray*. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor, ACS Chem. Biol. 2013, 8(10): 2145–2150.
  7. Feiyang Liu#, Xin Zhang#, Ellen Weisberg#, Sen Chen#, Wooyoung Hur, Hong Wu, Zheng Zhao, Wenchao Wang, Mao Mao, and Changmeng Cai, Nicholas I. Simon, Takaomi Sanda, Jinhua Wang, A. Thomas Look, James D. Griffin,Steven P. Balk*, Qingsong Liu*, Nathanael S. Gray*. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem. Biol. 2013, 8(7): 1423-1428.
  8. Feiyang Liu, Yijin Wang, Ming Yan, Luyong Zhang, Tao Pang*, Hong Liao*, Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons. Neurosci. Lett. 2013, 557B: 90-94.
  9. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide(CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. J. Med. Chem. 2016, 59(18): 8456-72.
  10. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou#, Cheng Chen#, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wan, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Xin Zhang*, Jing Liu*, Qingsong Liu*. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7(33): 53515-53525.
  11. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Wang Li,, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget 2016, 7(22): 32641-51.
  12. Ellen Weisberg#*, Atsushi Nonami#, Zhao Chen, Feiyang Liu, Jianming Zhang, Martin Sattler, Erik Nelson, Kristen Cowens, Amanda L. Christie, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael Gray, James D. Griffin*. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 2015, 29(1): 27-37.
  13. Ellen Weisberg#*, Atsushi Nonami#, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, Haeyeon Cho, Jianming Zhang, Martin Sattler, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael Gray, James D. Griffin*.Up-regulation of IGF-1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small molecule inhibition of IGF-1R. Clin. Cancer Res. 2014, 20(21): 5483–5495.
  14. Ellen Weisberg#*, Qingsong Liu#, Xin Zhang, Erik Nelson, Martin Sattler, Feiyang Liu, Maria Nicolais, Jianming Zhang, Constantine Mitsiades, Robert W. Smith, Richard Stone, Ilene Galinsky, Atsushi Nonami, James D. Griffin*, Nathanael Gray*. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One 2013, 8(2): e56473.
  15. Abdel Kareem Azab#*, Ellen Weisberg #, I Sahin, Feiyang Liu, Rana A.wwad, Feda Azab, Qingsong Liu, James D. Griffin, Irene M. Ghobrial.The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression, Leukemia 2013, 27(4): 961-964.
  16. Jing Liu, Feiyang Liu, David L Waller, Junfeng Wang, Qingsong Liu*. Kinase inhibitors targeting anti-angiogenesis as anti-cancer therapies. Current Angiogenesis 2012, 1(4): 335-346.

Publications

  1. 发明名称：一种新型的PDGFR激酶抑制剂及其用途
    发明人： 刘青松，刘静， 王强， 刘飞扬，亓爽，王蓓蕾，王文超，王傲莉，王伟，陈程，刘晓川，蒋宗儒，胡祯全，任涛，王黎
  2. 发明名称：一种选择性的C-KIT激酶抑制剂
    发明人： 刘青松，刘静，王强，王蓓蕾，刘飞扬，亓爽，齐紫平，邹凤鸣，陈程，王文超，胡晨，刘晓川，王伟，王傲莉，王黎，胡祯全，任涛
  3. 发明名称：一种新型结构的激酶抑制剂
    发明人：刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎
    专利受理号：201410757626.7